Frost & Sullivan, a global research and consulting organization, and Rani Therapeutics announced the results of a research study that points the way for biosimilar companies to take market share from blockbuster drugs, and for pharmaceutical companies with blockbusters to protect their position. Large molecule drugs such as anti-TNF alpha antibodies (Humira and Enbrel), are currently only available…